OncoMed Pharmaceuticals, Inc. Announces Presentations of Anti-Notch2/3 and Demcizumab Clinical Data at European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Meeting
11/9/2012 11:21:44 AM
DUBLIN--(BUSINESS WIRE)--OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced multiple presentations of clinical data on its Anti-Notch2/3 and demcizumab programs at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. Phase I clinical data on Anti-Notch2/3 were featured in an oral plenary session and additional clinical biomarker data were presented in a poster session. Demcizumab Phase Ib clinical data in non-small cell lung cancer patients were also featured in a separate poster session.